Save information for later
Sign Up

Learn About Myeloproliferative Neoplasms (MPN)

What is the definition of Myeloproliferative Neoplasms (MPN)?
Myeloproliferative neoplasms are rare blood cancers caused by the body making too many red blood cells, white blood cells, or platelets. There are several types of myeloproliferative neoplasms, including chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia.
What are the symptoms of Myeloproliferative Neoplasms (MPN)?
Symptoms of myeloproliferative neoplasms may not appear for years. Symptoms of myeloproliferative neoplasms depend on the type. The most common symptom is discomfort or pressure on the left side below the ribs due to an enlarged spleen. Other symptoms may include bone pain; night sweats; fever; fatigue; bruising easily; loss of appetite; unexplained weight loss; unexplained bleeding; blood in the urine; headaches; dizziness; blurred or double vision; pale or itchy skin; abdominal fullness; reddened face; weakness; shortness of breath; hearing problems; cough; swelling of the face, throat, hands or feet; muscle pain; and diarrhea.
Not sure about your diagnosis?
Check Your Symptoms
What are the different types of Myeloproliferative Neoplasms (MPN)?

Common conditions include: Myelofibrosis

What are the current treatments for Myeloproliferative Neoplasms (MPN)?
There is currently no cure for myeloproliferative neoplasms. Treatment for myeloproliferative neoplasms is focused on relieving the symptoms and preventing complications. Treatments for myeloproliferative neoplasms include watchful waiting, phlebotomy, platelet apheresis, transfusion therapy, chemotherapy, radiation therapy, drug therapy, immunotherapy, targeted therapy, chemotherapy, and stem cell transplant.
Who are the top Myeloproliferative Neoplasms (MPN) Local Doctors?
Ruben A. Mesa
Elite in Myeloproliferative Neoplasms (MPN)
Hematology | Oncology
Elite in Myeloproliferative Neoplasms (MPN)
Hematology | Oncology

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Mesa is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is currently accepting new patients.

Brady Stein
Elite in Myeloproliferative Neoplasms (MPN)
Hematology
Elite in Myeloproliferative Neoplasms (MPN)
Hematology
233 E Superior St 1st Fl, Olson Pavilion, 
Chicago, IL 
Languages Spoken:
English
Offers Telehealth

Brady Stein is a Hematologist in Chicago, Illinois. Dr. Stein is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Polycythemia Vera, Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Essential Thrombocythemia.

 
 
 
 
Learn about our expert tiers
Learn More
Aaron Gerds
Elite in Myeloproliferative Neoplasms (MPN)
Hematology Oncology | Hematology | Oncology
Elite in Myeloproliferative Neoplasms (MPN)
Hematology Oncology | Hematology | Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
Experience:
24+ years
Languages Spoken:
English
Offers Telehealth

Aaron Gerds is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Gerds has been practicing medicine for over 24 years and is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant.

What are the latest Myeloproliferative Neoplasms (MPN) Clinical Trials?
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

Summary: Low-dose MTX is a widely used, inexpensive, and safe therapy used for decades and is well tolerated by patients with rheumatologic diseases. Recently, it was identified as a type 2 JAK inhibitor. If MTX proves to be safe and tolerable with a signal of clinical activity, this could have a significant benefit to patients with MPNs. Beyond the potential benefit of adding a type 2 JAK inhibitor to cur...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms

Summary: The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).